Cargando…

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

BACKGROUND: Although co-inhibition of the angiogenesis and programmed death 1 (PD-1) pathways is proposed as an effective anticancer strategy, studies in Chinese patients with endometrial cancer are sufficient. Anlotinib is an oral multi-targeted tyrosine kinase inhibitor affecting tumor angiogenesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Wei, Ban, Xiaohua, Yang, Fan, Li, Jibin, Cheng, Xiaqin, Zhang, Rong, Huang, Xin, Huang, Yongwen, Li, Qiaqia, Qiu, Ya, Zheng, Min, Zhu, Xiaofeng, Li, Jundong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150151/ https://www.ncbi.nlm.nih.gov/pubmed/35623659 http://dx.doi.org/10.1136/jitc-2021-004338

Ejemplares similares

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
por: Chen, Xiaofeng, et al.
Publicado: (2023)

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
por: Xia, Lingfang, et al.
Publicado: (2022)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022)

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
por: Hua, Yijun, et al.
Publicado: (2021)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
por: Awada, Gil, et al.
Publicado: (2020)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
por: Qu, Yuan-Yuan, et al.
Publicado: (2022)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
por: Feng, Kaichao, et al.
Publicado: (2020)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
por: Han, Xiao, et al.
Publicado: (2022)

SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA
por: Wu, Ruiyan, et al.
Publicado: (2020)

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
por: Zhang, Wenwen, et al.
Publicado: (2023)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
por: Zakharia, Yousef, et al.
Publicado: (2021)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
por: Zhong, Hua, et al.
Publicado: (2023)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
por: Fizazi, Karim, et al.
Publicado: (2022)

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
por: Xu, Qin, et al.
Publicado: (2022)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

A new oncolytic Vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery
por: Ahmed, Jahangir, et al.
Publicado: (2020)

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
por: Antill, Yoland, et al.
Publicado: (2021)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
por: Atkinson, Victoria, et al.
Publicado: (2020)

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
por: Glutsch, Valerie, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
por: Slingluff, Jr., Craig L, et al.
Publicado: (2021)

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2021)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis
por: Zhang, Siqi, et al.
Publicado: (2022)

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8h7odn3k8c38afm6tddh538hg0